Laurion Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Laurion Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31,200	Closed	-$150K	–	620
2023 Q3	$150K	Buy	+31,200	New	+$156K	﹤0.01%	436
2023 Q2	–	Sell	-571,200	Closed	-$3.14M	–	708
2023 Q1	$3.14M	Hold	571,200	–	–	0.02%	257
2022 Q4	$2.62M	Hold	571,200	–	–	0.01%	300
2022 Q3	$3.56M	Sell	571,200 -11,061	-2%	-$62.6K	0.02%	281
2022 Q2	$2.6M	Buy	+582,261	New	+$2.65M	0.04%	209

Other funds holding ZVRA

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Laurion Capital Management's ZVRA Position: Q4 2023 in Review

Laurion Capital Management sold out of Zevra Therapeutics (ZVRA) in Q4 2023, closing a stake of 31,200 shares — an estimated $150K sold.

Laurion Capital Management first reported a position in ZVRA in Q2 2022 and held it in 5 quarters. The position peaked at $3.56M in Q3 2022. 84 funds tracked by Wall St. Rank hold ZVRA as of Q4 2023.

Laurion Capital Management reported no remaining Zevra Therapeutics position as of Q4 2023 after selling out during the quarter.
Laurion Capital Management sold 31,200 Zevra Therapeutics shares in Q4 2023, an estimated $150K.
Laurion Capital Management first reported a position in Zevra Therapeutics in Q2 2022 and held it in 5 quarters.
Laurion Capital Management's Zevra Therapeutics position peaked at $3.56M in Q3 2022.
84 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.